Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

The polymer drug delivery system was developed at the Massachusetts Institute of Technology and licensed to Nova in 1986

  • News

Executive Summary

Soon after Nova licensed the biodegradable polymer from MIT, the Baltimore firm signed a $10 mil. research/equity investment agreement with Celanese to pursue drug delivery systems ("The Pink Sheet" March 31, 1986, T&G-1). In the current trials, the biodegradable polymer will be used with the anti-cancer generic drug BCNU. After a brain tumor is removed, the polymer/BCNU will be implanted into the patient's brain, releasing high concentrations of the drug in an attempt to destroy any remaining cancer cells. Nova has worldwide exclusive rights to all pharmaceutical applications of the drug delivery technology.

Table

View full table

Tags:
Latest Headlines

US FDA Inspectors, Product Centers Working Closer Together Ahead Of ORA Reorg

Not-For-Profit Models Needed For Commercially Unviable Rare Disease Drugs

EU Urban Wastewater Directive Update ‘Unfairly Targets Pharmaceutical Industry’

Swissmedic Gets New Grant For Regulatory Strengthening In LMICs

See All
UsernamePublicRestriction

Register

PS012224

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By